Skip to Main Content

Paper Details

Doxorubicin pharmacokinetics and toxicity in patients with aggressive lymphoma and hepatic impairment.
Blood Adv
1
2023
Aggressive Lymphoma, Doxorubicin, EPOCH, Hepatic Impairment, Patients, bilirubin, doxorubicin, doxorubicinol, febrile neutropenia, gastrointestinal and neurotoxicity, lymphomas, patients, rituximab, thrombocytopenia
Author NameAffiliation
Seth M SteinbergCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Seth M SteinbergCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Brigitte C WidemannCenter for Cancer Research, National Cancer Institute, National Institutes of Health
  • 1 - 3

Datasets

Release 1.2